ImmunityBio (IBRX) Non-Current Debt (2020 - 2026)

ImmunityBio (IBRX) has 7 years of Non-Current Debt data on file, last reported at $404.3 million in Q1 2026.

• Non-Current Debt for Q1 2026 came in at $404.3 million, up 36.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $404.3 million (up 36.46% YoY), and the FY2025 annual result was $324.6 million, up 14.14% from the prior year.
• Non-Current Debt grew to $404.3 million in Q1 2026 per IBRX's latest filing, from $324.6 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $480.0 million in Q3 2023 and troughed at $155.4 million in Q4 2023.
• A 5-year average of $300.6 million and a median of $307.0 million in 2025 frame the typical range for Non-Current Debt.
• On a YoY basis, Non-Current Debt climbed as much as 83.0% in 2024 and fell as far as 42.99% in 2024.
• A 5-year view of Non-Current Debt shows it stood at $373.3 million in 2022, then plunged by 58.37% to $155.4 million in 2023, then surged by 83.0% to $284.4 million in 2024, then increased by 14.14% to $324.6 million in 2025, then gained by 24.55% to $404.3 million in 2026.
• Business Quant data shows IBRX's Non-Current Debt at $404.3 million in Q1 2026, $324.6 million in Q4 2025, and $316.1 million in Q3 2025.